Saltar al contenido
Merck

Long-term loss of osteoclasts and unopposed cortical mineral apposition following limited field irradiation.

Journal of orthopaedic research : official publication of the Orthopaedic Research Society (2014-11-20)
Megan E Oest, Veerle Franken, Timothy Kuchera, Judy Strauss, Timothy A Damron
RESUMEN

Late-onset fragility fractures are a common complication following radiotherapy for metastatic disease and soft tissue sarcomas. Using a murine hindlimb focal irradiation model (RTx), we quantified time-dependent changes in osteoclasts and mineral apposition rate (MAR). Mice received either a single, unilateral 5 Gy exposure or four fractionated doses (4 × 5 Gy). Osteoclast numbers and MAR were evaluated histologically at 1, 2, 4, 8, 12, and 26 weeks post-RTx. Radiation induced an early, transient increase in osteoclasts followed by long-term depletion. Increased osteoclast numbers correlated temporally with trabecular resorption; the resorbed trabeculae were not later restored. Radiotherapy did not attenuate MAR at any time point. A transient, early increase in MAR was noted in both RTx groups, however, the 4 × 5 Gy group exhibited an unexpected spike in MAR eight weeks. Persistent depletion of osteoclasts permitted anabolic activity to continue unopposed, resulting in cortical thickening. These biological responses likely contribute to post-radiotherapy bone fragility via microdamage accumulation and matrix embrittlement in the absence of osteoclastic remodeling, and trabecular resorption-induced decrease in bone strength. The temporal distribution of osteoclast numbers suggests that anti-resorptive therapies may be of clinical benefit only if started prior to radiotherapy and continued through the following period of increased osteoclastic remodeling.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Metilmetacrilato, contains ≤30 ppm MEHQ as inhibitor, 99%
Sigma-Aldrich
Luperox® A75, Benzoyl peroxide, 75%, remainder water
Sigma-Aldrich
Methyl benzoate, 99%
Sigma-Aldrich
L-Lysine monohydrochloride, from non-animal source, meets EP, JP, USP testing specifications, suitable for cell culture, 98.5-101.0%
Sigma-Aldrich
Butyl methacrylate, 99%, contains monomethyl ether hydroquinone as inhibitor
Sigma-Aldrich
Metilmetacrilato, 99%, stabilized
Sigma-Aldrich
Luperox® A75FP, Benzoyl peroxide, 75% remainder water, contains 25 wt. % water as stabilizer, 75%
Sigma-Aldrich
Luperox® A98, Benzoyl peroxide, reagent grade, ≥98%
Sigma-Aldrich
L-Lysine monohydrochloride, reagent grade, ≥98% (HPLC)
Sigma-Aldrich
Benzoyl peroxide blend with dicyclohexyl phthalate, suitable for use as a catalyst for electron microscopy. Modified to render it safe in transit.
Sigma-Aldrich
Methyl benzoate, ≥98%, FCC, FG
Sigma-Aldrich
Luperox® AFR40, Benzoyl peroxide solution, 40 wt. % in dibutyl phthalate
Sigma-Aldrich
Methyl benzoate, natural, ≥98%, FCC, FG
Supelco
Methyl benzoate, analytical standard
Supelco
L-Lysine monohydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
L-Lysine monohydrochloride, BioUltra, ≥99.5% (AT)
Lysine hydrochloride, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
β-D-Allose, rare aldohexose sugar
Metilmetacrilato, European Pharmacopoeia (EP) Reference Standard
Supelco
L-Lysine hydrochloride solution, 100 mM amino acid in 0.1 M HCl, analytical standard
Supelco
L-Lysine monohydrochloride, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Butyl methacrylate, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Metilmetacrilato, SAJ first grade, ≥99.0%
Sigma-Aldrich
L-Lysine monohydrochloride, SAJ special grade, ≥99.0%